Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial

Abstract Background As 40–60% of the patients with obsessive-compulsive disorder (OCD) do not adequately respond to the first-line treatment, finding an effective second-line treatment is required. Our aim was to assess the efficacy and safety of agomelatine (a selective melatonin receptor agonist a...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Marjan Shokrani, Sanaz Askari, Negin Eissazade, Seyed Vahid Shariat, Behnam Shariati, Masoomeh Yarahmadi, Mohammadreza Shalbafan
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMC 2023-09-01
Serie:	BMC Psychiatry
Ämnen:	Agomelatine Obsessive-compulsive disorder Sertraline Selective serotonin reuptake inhibitors
Länkar:	https://doi.org/10.1186/s12888-023-05189-7
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!